This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Dana-Farber-Cancer Institute Inc.. Active years: 2020-2023.
Company Filing History:
Years Active: 2020-2023
Title: Innovations of Xinqi Wu in Melanoma Research
Introduction
Xinqi Wu is a notable inventor based in Chestnut Hill, MA (US), recognized for his contributions to the field of melanoma research. He holds two patents that focus on innovative methods for identifying and treating melanoma, a serious form of skin cancer. His work is instrumental in advancing the understanding and management of this disease.
Latest Patents
Xinqi Wu's latest patents include significant advancements in melanoma treatment. The first patent, titled "Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms," relates to compositions and methods for identifying, assessing, preventing, and treating melanoma. This invention provides a variety of PD-L1 isoform biomarkers, wherein alterations in the copy number of these biomarkers are associated with melanoma status. The second patent, "Anti-galectin antibody biomarkers predictive of anti-immune checkpoint and anti-angiogenesis responses," is based on the identification of novel biomarkers that predict responsiveness to a combination of anti-immune checkpoint and anti-angiogenesis therapies.
Career Highlights
Xinqi Wu is affiliated with the Dana-Farber Cancer Institute Inc., where he continues to contribute to cancer research and innovation. His work has garnered attention for its potential to improve treatment outcomes for melanoma patients.
Collaborations
Some of Xinqi Wu's notable coworkers include F Stephen Hodi and Jingjing Li, who collaborate with him on various research initiatives aimed at enhancing cancer treatment strategies.
Conclusion
Xinqi Wu's innovative patents and research efforts play a crucial role in the fight against melanoma. His contributions are paving the way for more effective treatment options and a better understanding of this challenging disease.